Sjogren's Syndrome Market Summary

• The Sjögren’s Disease Market is expected to grow steadily across major regions, driven by improved diagnosis, rising awareness, and the development of targeted and biologic therapies. The United States is expected to hold the largest share, followed by the EU4, the United Kingdom, and Japan.
• The leading Sjögren’s Disease Companies include ADVANZ Pharma, Daiichi Sankyo, Resolve Therapeutics, GlaxoSmithKline, VIELABIO, RemeGen, Bristol Myers Squibb, TearSolutions, Pfizer Inc., AstraZeneca plc, Novartis AG, Sanofi S.A., Roche Holding AG, Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Biogen Inc., Amgen Inc., Celgene Corporation, Genentech, Inc, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Bayer AG, and others.

Sjogren's Disease Market and Epidemiology Analysis

• Sjögren’s disease represents a major public health burden in the United States, affecting up to 4 million individuals, with approximately 2.5 million patients still undiagnosed despite its systemic and progressive nature. 
• The disease burden is mainly driven by autoimmune gland damage, with risk factors such as female predominance, older age, and associated autoimmune conditions. Ongoing immune-mediated inflammation highlights the need for early diagnosis and better targeted treatment options.
• Among antigen-specific cases of Sjogren’s disease, auto-antibodies (+ve) cases were highest, followed by anti-Ro/SSA (+ve), and then anti-La/SSB (+ve).
• Classification and assessment systems for Sjögren’s disease include American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Classification Criteria, the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), and the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), which are used for diagnosis, disease activity scoring, symptom evaluation, and monitoring systemic involvement over time.
• Despite the significant disease burden, no disease-modifying therapies are currently approved for Sjögren’s disease, and management mainly relies on symptomatic care such as artificial tears, saliva substitutes, pilocarpine, cevimeline, and off-label immunosuppressants. These approaches relieve symptoms but do not address underlying autoimmune activity and are associated with variable efficacy and persistent disease burden.
• The Sjogren's Syndrome Pipeline focuses on biologics and immunomodulators targeting B-cell activity and inflammation. Key investigational therapies include Telitacicept (Vor Biopharma), Dazodalibep (Amgen), Nipocalimab (Johnson & Johnson), Deucravacitinib (SOTYKTU; Bristol-Myers Squibb), Lanalumab (VAY736; Novartis), IMVT-1402 (Immunovant Sciences), Rapcabtagene autoleucel (YTB323; Novartis), evaluated across clinical stages.
• As the pipeline matures, the Sjogren's Syndrome Competitive Landscape is expected to evolve from symptomatic care toward precision immunology, with future therapies aiming to modify disease progression, improve systemic outcomes, and address the substantial unmet needs of a largely underserved patient population. 

Sjogren's Disease Market Size and Forecast in the 7MM

Key Factors Driving the Sjogren’s Disease Market Growth

• Rising Sjogren’s Disease Prevalence

The increasing prevalence of Sjogren’s disease, particularly among females, is a primary driver of Sjogren’s disease market expansion, supported by improving disease awareness, advancements in diagnostic approaches, earlier detection rates, and the ongoing development of targeted therapeutic options. 

• Emerging Sjögren’s Disease Competitive Landscape

The Sjögren’s disease treatment landscape is evolving with the development of targeted immunotherapies, FcRn inhibitors, TYK2 inhibitors, and cell therapies design to address the underlying autoimmune drivers of the disease. Key Sjogren's Syndrome Emerging Therapies, including Telitacicept, Dazodalibep, Nipocalimab, Deucravacitinib (SOTYKTU), Lanalumab (VAY736), IMVT-1402, and Rapcabtagene autoleucel (YTB323), aim to modulate B-cell activity, reduce pathogenic autoantibodies and inflammation, improve glandular function, and provide disease-modifying alternatives to current symptomatic treatments.

DelveInsight's ‘Sjogren's Disease Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the Sjogren's disease, historical and forecasted epidemiology, as well as the Sjogren’s disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Sjogren's disease Treatment Market Report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Sjogren’s disease patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in Sjogren’s disease and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Sjogren’s Disease Understanding and Treatment Algorithm

Sjogren’s Disease Overview and Diagnosis

Sjögren’s disease is a chronic autoimmune disorder characterized by immune-mediated damage to the salivary and lacrimal glands, resulting in dry mouth and dry eyes. It can occur as a primary condition or alongside other autoimmune diseases such as Rheumatoid Arthritis and Systemic Lupus Erythematosus. The disease predominantly affects middle-aged women and is associated with genetic, hormonal, and environmental factors. In addition to glandular symptoms, Sjögren’s disease may cause systemic complications involving multiple organs, leading to significant long-term morbidity and reduced quality of life.

Sjögren’s disease is diagnosed through a comprehensive clinical evaluation, assessment of characteristic sicca symptoms, serological testing, and objective measures of glandular dysfunction. Key diagnostic modalities include anti-SSA/Ro and anti-SSB/La antibody testing, antinuclear antibody (ANA) and rheumatoid factor assessment, Schirmer’s test, ocular surface staining, salivary flow measurement, salivary gland imaging, and, where appropriate, minor salivary gland biopsy.

Additional investigations may be undertaken to evaluate systemic manifestations, establish disease severity, support risk stratification, and inform long-term disease management and monitoring.

Sjogren’s Disease Treatment

The primary goals of Sjögren’s disease treatment are to relieve symptoms, improve quality of life, and prevent disease complications. Management is largely symptomatic, with dry eye and dry mouth treated using artificial tears, saliva substitutes, and secretagogues. Patients with systemic manifestations may require corticosteroids, immunosuppressants, or biologic therapies.

While no disease-modifying therapy is specifically approved for Sjögren’s disease, several targeted therapies are currently under clinical development.

Sjogren’s Disease Unmet Needs

The section “unmet needs of Sjogren’s Disease” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress. 

1. Lack of effective disease-modifying therapies
2. Delayed diagnosis and limited diagnostic biomarkers
3. Limited options for systemic disease management
4. Need for biomarkers to predict disease progression and treatment response, and others…..

Sjogren’s Disease Epidemiology

Key Findings from Sjogren’s Disease Epidemiological Analysis and Forecast 

• As per DelveInsight’s analysis, in 2025, the total Sjogren's disease Diagnosed Prevalent Cases were ~3,350,000 in the 7MM, which are expected to increase during the forecast period, i.e., 2026–2036.
• In 2025, the Sjogren's Syndrome Diagnosed Prevalent Cases were the highest in the US, accounting for ~1,800,000 cases which are estimated to increase by 2036.
• Among the EU4 & the UK, the UK reported the highest diagnosed prevalent cases of Sjogren’s disease in 2025, followed by Germany, while Spain reported the least diagnosed prevalence across the major European markets.
• In 2025, the diagnosed prevalent cases of Sjögren’s disease were approximately ~180,000 in males, while females accounted for ~1,620,000 cases, significantly higher than males, in the US.
• In Japan, Sjögren’s disease exhibits a marked female predominance, with women accounting for 94.2% of diagnosed cases in 2025.

Sjogren's Disease Epidemiology Segmentation in the 7MM

• Sjogren’s Disease Diagnosed Prevalent Cases
• Sjogren’s Disease Type-specific Diagnosed Prevalent Cases
• Sjogren’s Disease Gender-specific Diagnosed Prevalent Cases
• Sjogren’s Disease Severity-specific Diagnosed Prevalent Cases
• Sjogren’s Disease Antigen-specific Diagnosed Prevalent Cases
• Total Sjogren’s Disease Treated Cases

Sjogren's Syndrome Market Recent Breakthroughs and Developments

• June 2026: RemeGen Co., Ltd. initiated a Phase III clinical trial to evaluate the efficacy and safety of telitacicept (RC18) in adults with active primary Sjögren's disease. Telitacicept is a recombinant fusion protein that targets B-cell-mediated immune pathways by combining the extracellular domain of TACI with the Fc portion of human IgG1, aiming to modulate abnormal B-cell activity associated with the disease.
• June 2026: Janssen Research & Development LLC announced the initiation of a Phase III clinical program evaluating nipocalimab in patients with moderate-to-severe Sjögren's disease (SjD). The program comprises two identical randomized, double-blind, placebo-controlled studies designed to assess the efficacy, safety, and tolerability of nipocalimab in adults aged 18 years and older.
• June 2026: Novartis Pharmaceuticals initiated the NEPTUNUS-2 Phase III trial to assess the efficacy, safety, and tolerability of ianalumab (VAY736) in patients with active Sjögren's syndrome. The three-arm study is evaluating monthly and every-three-month subcutaneous dosing of ianalumab compared with placebo to determine its clinical benefit in managing active disease.
• June 2026: Immunovant Sciences GmbH commenced a Phase IIb study investigating IMVT-1402 in adults with moderate-to-severe systemic primary Sjögren's disease. The trial is designed to evaluate the therapy's efficacy, safety, and tolerability, with the primary endpoint measuring changes in the Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ClinESSDAI) at Week 24.
• June 2026: Lubris Bio Pty Ltd launched a Phase II clinical study in Australia to evaluate the safety and efficacy of topically administered rhPRG4 for the treatment of Sjögren's disease-associated Dry Eye Disease. The study aims to determine the therapeutic potential of rhPRG4 in improving ocular symptoms and disease outcomes in affected patients.

Sjogren’s Disease Drug Analysis & Competitive Analysis

The Sjogren’s disease drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I–III Sjogren's Syndrome Clinical Trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments.

This section offers critical insights into the Sjogren’s disease treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Sjogren’s disease therapeutics market.

Sjogren’s Disease Approved Therapies

Despite advances in understanding the pathogenesis of Sjögren’s disease, there are currently no approved disease-modifying therapies specifically indicated to treat the underlying condition. Management primarily focuses on symptomatic relief through artificial tears, saliva substitutes, secretagogues, and immunomodulatory agents used off-label for systemic manifestations.

This reliance on supportive care highlights the significant need for targeted therapies that can effectively control disease activity, preserve glandular function, and improve long-term patient outcomes.

Sjogren’s Disease Pipeline Analysis

• Telitacicept (RC18):  Vor Biopharma

Telitacicept is a recombinant fusion protein being developed for Sjögren’s disease that targets both B-lymphocyte stimulator (BLyS/BAFF) and a proliferation-inducing ligand (APRIL), key cytokines involved in B-cell activation and autoantibody production It is being developed by Vor Biopharma, which obtained exclusive development and commercialization rights outside Greater China from RemeGen in June 2025.

The therapy is already approved in China for Generalized Myasthenia Gravis, Systemic Lupus Erythematosus, and rheumatoid arthritis, with regulatory applications under review for Sjögren’s disease and IgA nephropathy. Supported by established clinical experience in multiple autoimmune indications, telitacicept is advancing through global development programs across North America, Europe, Latin America, and Asia, positioning it as a promising potential disease-modifying therapy for Sjögren’s disease.

Topline results from its ongoing global Phase III study are anticipated in H1 2027, representing an important catalyst for its broader regulatory and commercial expansion.

• Dazodalibep: Amgen

Dazodalibep, developed by Amgen, is an investigational biologic therapy for Sjögren’s Disease that targets the CD40-CD40L pathway involved in autoimmune inflammation. By blocking CD40L-mediated immune activation, the therapy aims to reduce disease activity, improve glandular function, and relieve symptoms such as dry eyes and dry mouth.

The therapy has demonstrated promising clinical efficacy and has the potential to emerge as a disease-modifying treatment option for patients with Sjögren’s disease. Dazodalibep is supported by composition-of-matter patents covering its polypeptide structure, with intellectual property protection extending until 2034 in the United States and 2032 in Europe, providing a strong foundation for long-term commercial exclusivity and lifecycle management.

Sjogren’s Disease Companies, Market Leaders and Emerging Companies

• Vor Biopharma
• Amgen
• Johnson & Johnson
• Bristol-Myers Squibb
• Novartis
• Immunovant Sciences GmbH, and others

Sjogren’s Disease Market Outlook

The Sjögren’s Disease market is undergoing a significant transformation, shifting beyond symptomatic management toward targeted therapies designed to address the underlying autoimmune mechanisms driving disease progression. The development of novel agents such as CD40L inhibitors, FcRn blockers, BAFF/APRIL-targeted therapies, TYK2 inhibitors, and cellular therapies reflects increasing efforts to achieve disease modification, improve glandular function, and reduce systemic manifestations.

These advancements are strengthening clinical and regulatory interest in innovative treatments and reshaping the competitive landscape. With the continued advancement of Sjogren's Syndrome Pipeline candidates such as dazodalibep, nipocalimab, telitacicept, deucravacitinib, and other emerging therapies.

The Sjögren’s disease treatment market landscape is evolving toward more targeted and personalized approaches. These therapies have the potential to address significant unmet needs by improving disease control, reducing symptom burden, and enhancing long-term patient outcomes.

Overall, increasing disease awareness, improved diagnostic capabilities, growing recognition of systemic disease burden, and ongoing innovation in immune-targeted therapies are expected to drive growth in the Sjögren’s Disease market during the forecast period, creating significant commercial opportunities for both future approved therapies and emerging pipeline products.

Key findings from Sjogren's Syndrome Market Forecast Report

• According to the estimates, the United States accounted for the largest share of the Sjogren’s disease market among the 7MM during the study period.
• The Sjögren’s Disease Market is evolving as treatment approaches shift from symptomatic management toward targeted immunomodulatory therapies, with emerging candidates such as Dazodalibep, Nipocalimab, and Telitacicept generating significant interest due to their potential to address underlying disease mechanisms, reduce autoimmune activity, and improve glandular function.
• Regional market dynamics show the United States leading in clinical development and commercial potential, while Europe and Japan demonstrate growing interest driven by increasing disease awareness, improved diagnostic capabilities, and continued advancement of novel biologics, FcRn inhibitors, and B-cell–targeted therapies.

Sjogren’s Disease Drug Class/Insights into Leading Emerging and Marketed Therapies (2022–2036 Forecast)

The Sjögren’s Disease market comprises symptomatic therapies, B-cell–targeted therapies, FcRn inhibitors, T-cell co-stimulation modulators, cytokine signaling inhibitors, and cellular immunotherapies, each addressing distinct mechanisms involved in autoimmune inflammation, glandular dysfunction, and systemic disease manifestations.

• B-cell–targeted therapies: Investigational therapies such as Telitacicept and Lanalumab (VAY736) target key B-cell survival pathways, including BLyS/APRIL and BAFF-R signaling, with the aim of reducing autoreactive B-cell activity and autoantibody production.
• FcRn inhibitors: Emerging agents such as Nipocalimab and IMVT-1402 inhibit the neonatal Fc receptor (FcRn), promoting the degradation of pathogenic IgG autoantibodies and reducing autoimmune-mediated tissue damage.
• T-cell co-stimulation modulators: Dazodalibep blocks the CD40-CD40L pathway, suppressing aberrant T-cell and B-cell interactions that contribute to chronic inflammation and disease progression.
• Cytokine signaling inhibitors: Deucravacitinib (SOTYKTU), a TYK2 inhibitor, modulates inflammatory cytokine signaling pathways implicated in autoimmune disease activity.

Symptomatic therapies currently dominate the Sjögren’s disease treatment landscape, while targeted immune-modulating agents and cellular therapies are driving future innovation and shaping the next generation of disease-modifying treatments.

Sjogren’s Disease Drug Uptake

This section focuses on the uptake rate of potential Sjogren's Syndrome drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the Sjogren’s disease market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Hyperkalemia Market Access and Reimbursement

The Sjogren's Syndrome therapeutics market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Sjogren’s Disease Therapies Price Scenario & Trends 

Pricing and analogue assessment of Sjogren’s disease therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Sjogren’s Disease Industry Experts and Physician Views

To keep up with Sjogren’s disease market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Sjogren’s disease emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Sjogren’s disease, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of Mississippi Medical Center, University of Bologna, and Teikyo University School of Medicine, etc. were contacted. Their opinion helps understand and validate current and emerging Sjogren’s disease therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Sjogren's Disease.

Sjogren's Syndrome Qualitative Analysis Report: SWOT and Conjoint Analysis

We perform qualitative and Sjogren's Syndrome Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of Sjögren’s disease, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Sjogren's Syndrome Market Report

• The Sjogren's Syndrome Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Sjogren's Syndrome Treatment landscape.
• A detailed review of the Sjogren’s Disease Therapeutics Market, historical and forecasted Sjogren's Syndrome Market Size, Sjogren's Syndrome Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Sjogren's Syndrome Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Sjogren's Syndrome Drugs Market.

Sjogren's Syndrome Market Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report 
• 11-year Sjogren's Syndrome Market Forecast 
• Sjogren’s Disease Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (by geography)
• Sjogren’s Disease Treatment Addressable Market (TAM)
• Sjogren’s Disease Competitive Landscape
• Sjogren’s Disease Major Companies Insights
• Sjogren’s Disease Price Trends and Analogue Assessment
• Sjogren’s Disease Therapies Drug Adoption/Uptake
• Sjogren’s Disease Therapies Peak Patient Share analysis

Sjogren's Syndrome Market Report Assessment

• Current Sjogren’s Disease Treatment Practices
• Sjogren’s Disease Unmet Needs
• Sjogren’s Disease Clinical Development Analysis
• Sjogren’s Disease Emerging Drugs Product Profiles
• Sjogren’s Disease Market Attractiveness
• Sjogren’s Disease Qualitative Analysis (SWOT and Conjoint Analysis)

Sjogren's Syndrome Market Report Insights

• Sjogren’s Disease Patient Population Forecast
• Sjogren’s Disease Therapeutics Market Size 
• Sjogren’s Disease Pipeline Analysis
• Sjogren’s Disease Market Size and Trends
• Sjogren’s Disease Market Opportunity (Current and Forecasted)

Key Questions Answered in the Sjogren's Syndrome Market Report

Sjogren's Syndrome Market Insights

• What was the Sjogren’s disease treatment market size, the market size by therapies, Sjogren's Syndrome drugs market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Sjogren’s disease?
• What are the disease risks, burdens, and unmet needs of Sjogren’s disease?
• What will be the growth opportunities across the 7MM concerning the patient population with Sjogren’s disease?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Sjogren’s disease? What are the current guidelines for treating Sjogren’s disease in the US, Europe, and Japan?

Reasons to Buy the Sjogren's Syndrome Market Report

• The Sjogren's Syndrome Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Sjogren’s disease Drugs Market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease Sjogren's Syndrome Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Sjogren's Syndrome Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Sjogren's Syndrome Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Sjogren's Syndrome Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) - enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.

Stay updated with us for Recent Articles

• Sjogren's syndrome- Autoimmune Attack on Salivary and Tear Glands
• Involvement of B cells in the pathogenesis of primary Sjögren syndrome
• Sjogren's Syndrome Market Infographics
• New DelveInsight Blogs